BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gallagher JC. Omadacycline: A Modernized Tetracycline. Clin Infect Dis 2019;69:S1-5. [PMID: 31367739 DOI: 10.1093/cid/ciz394] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 7.5] [Reference Citation Analysis]
Number Citing Articles
1 Pfaller MA, Huband MD, Shortridge D, Flamm RK. Surveillance of Omadacycline Activity Tested against Clinical Isolates from the United States and Europe: Report from the SENTRY Antimicrobial Surveillance Program, 2016 to 2018. Antimicrob Agents Chemother 2020;64:e02488-19. [PMID: 32071045 DOI: 10.1128/AAC.02488-19] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Meir M, Barkan D. Alternative and Experimental Therapies of Mycobacterium abscessus Infections. Int J Mol Sci 2020;21:E6793. [PMID: 32948001 DOI: 10.3390/ijms21186793] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
3 Brown-Elliott BA, Wallace RJ Jr. In Vitro Susceptibility Testing of Omadacycline against Nontuberculous Mycobacteria. Antimicrob Agents Chemother 2021;65:e01947-20. [PMID: 33288634 DOI: 10.1128/AAC.01947-20] [Reference Citation Analysis]
4 Karaman R, Jubeh B, Breijyeh Z. Resistance of Gram-Positive Bacteria to Current Antibacterial Agents and Overcoming Approaches. Molecules 2020;25:E2888. [PMID: 32586045 DOI: 10.3390/molecules25122888] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 6.5] [Reference Citation Analysis]
5 Boyd SE, Livermore DM, Hooper DC, Hope WW. Metallo-β-Lactamases: Structure, Function, Epidemiology, Treatment Options, and the Development Pipeline. Antimicrob Agents Chemother 2020;64:e00397-20. [PMID: 32690645 DOI: 10.1128/AAC.00397-20] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 11.0] [Reference Citation Analysis]
6 Kuo SC, Wang YC, Tan MC, Huang WC, Shiau YR, Wang HY, Lai JF, Huang IW, Lauderdale TL. In vitro activity of imipenem/relebactam, meropenem/vaborbactam, ceftazidime/avibactam, cefepime/zidebactam and other novel antibiotics against imipenem-non-susceptible Gram-negative bacilli from Taiwan. J Antimicrob Chemother 2021;76:2071-8. [PMID: 33956969 DOI: 10.1093/jac/dkab141] [Reference Citation Analysis]
7 Singh KV, Murray BE. Efficacy of Omadacycline against Escherichia coli in a Mouse Urinary Tract Infection Model. Antimicrob Agents Chemother 2021;65:e0026921. [PMID: 33972239 DOI: 10.1128/AAC.00269-21] [Reference Citation Analysis]
8 Vrancianu CO, Dobre EG, Gheorghe I, Barbu I, Cristian RE, Chifiriuc MC. Present and Future Perspectives on Therapeutic Options for Carbapenemase-Producing Enterobacterales Infections. Microorganisms 2021;9:730. [PMID: 33807464 DOI: 10.3390/microorganisms9040730] [Reference Citation Analysis]
9 Liu PY, Ko WC, Lee WS, Lu PL, Chen YH, Cheng SH, Lu MC, Lin CY, Wu TS, Yen MY, Wang LS, Liu CP, Shao PL, Lee YL, Shi ZY, Chen YS, Wang FD, Tseng SH, Lin CN, Chen YH, Sheng WH, Lee CM, Tang HJ, Hsueh PR. In vitro activity of cefiderocol, cefepime/enmetazobactam, cefepime/zidebactam, eravacycline, omadacycline, and other comparative agents against carbapenem-non-susceptible Pseudomonas aeruginosa and Acinetobacter baumannii isolates associated from bloodstream infection in Taiwan between 2018-2020. J Microbiol Immunol Infect 2021:S1684-1182(21)00186-9. [PMID: 34521591 DOI: 10.1016/j.jmii.2021.08.012] [Reference Citation Analysis]
10 Chopra T, Sandhu A, Theriault N, Meehan J, Tillotson G. Omadacycline: a therapeutic review of use in community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. Future Microbiol 2020;15:1319-33. [PMID: 32959689 DOI: 10.2217/fmb-2020-0182] [Reference Citation Analysis]
11 Hobson C, Chan AN, Wright GD. The Antibiotic Resistome: A Guide for the Discovery of Natural Products as Antimicrobial Agents. Chem Rev 2021;121:3464-94. [PMID: 33606500 DOI: 10.1021/acs.chemrev.0c01214] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 11.0] [Reference Citation Analysis]
12 Sharma R, Sandrock CE, Meehan J, Theriault N. Community-Acquired Bacterial Pneumonia-Changing Epidemiology, Resistance Patterns, and Newer Antibiotics: Spotlight on Delafloxacin. Clin Drug Investig 2020;40:947-60. [PMID: 32889706 DOI: 10.1007/s40261-020-00953-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Morrisette T, Alosaimy S, Philley JV, Wadle C, Howard C, Webb AJ, Veve MP, Barger ML, Bouchard J, Gore TW, Lagnf AM, Ansari I, Mejia-Chew C, Cohen KA, Rybak MJ. Preliminary, Real-world, Multicenter Experience With Omadacycline for Mycobacterium abscessus Infections. Open Forum Infect Dis 2021;8:ofab002. [PMID: 33628856 DOI: 10.1093/ofid/ofab002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]